Enter your keyword

Efficiently Creating Value with Innovative Science

Press Release

Feb 22, 2021
MATEON THERAPEUTICS AND WINDLAS BIOTECH LAUNCH INDIA’S FIRST COMBINED LUNG THERAPY AND AI TELEMEDICINE 360° SOLUTION TO TRANSFORM RESPIRATORY WELLNESS AT WWW.PULMOHEAL.COM

AGOURA HILLS, California, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB:MATN) (“Mateon”), a leading developer of TGF-β therapeutics for oncology and infectious disease and respiratory health and Windlas Biotech Pvt. Ltd. (Windlas), a leading Indian pharmaceutical contract drug development and manufacturing organization, announced today the launch in India of PulmoHeal a first-of-its-kind integrated, consumer-centric solution for respiratory wellness.

The combined drug + AI telemedicine 360o care solution is designed to support the estimated 100 million people in India who suffer from respiratory problems and address the underlying challenges of a lack of cost-effective and lab-free methods for early diagnosis of diseases.

PulmoHeal consists of three components:

  • the drug PulmoHeal, a broad-spectrum, lung therapy food supplement that is supported by a multi-centre rigorous clinical study that has demonstrated efficacy against a viral respiratory infection- COVId-19;
  • a mobile app called ArtiHealth powered by Mateon’s AI supercomputing platform that allows patients to submit a questionnaire and a daily cough recording to receive real-time information on their respiratory function and progress over time; and
  • a post-marketing survey (PMS) platform to crowd-source user experience for new indications. 
  • Additional information at www.pulmoheal.com

Artemisinin - the active component in PulmoHeal- is derived from the extract of the indigenous plant Artemisia, which has exhibited multiple pharmacological activity against inflammation, viral infections, and lung repair.

Online channels include Amazon, Flipkart and 1mg.com, PulmoHeal can be taken periodically by those affected by respiratory viral infection, asthma, hay fever, or smokers and even those living in smog infested cities to improve their lung health and breathing functions. Additional information at www.pulmoheal.com

Mr Hitesh Windlass, MD, Windlas Biotech, commented, "Windlas, with its US partner Mateon, is the first company in the world to bring forward an integrated consumer-centric solution to respiratory health. PulmoHeal is a unique combination of cutting-edge manufacturing, clinical drug development, and AI, which harnesses the power of traditional and modern science. The ARTIHealth model can be replicated for a range of therapies, including monitoring COVID-19 infection. Our work with Mateon on PulmoHeal has been accepted by leading peer-reviewed journals in modern medicine and we shall continue to build on our momentum in bringing 360o solution to all facets of healthcare.”

Saran Saund, CBO and GM of AI Division, Mateon, commented, “To date, standard of care for mild and moderate COVID-19 patients is primarily limited to self-quarantine due to a significant strain of medical resources, without any drug therapy. Such patients can benefit from PulmoHeal. We are optimistic that our solution will be beneficial even beyond current pandemic by empowering the patients and reducing burden on health care providers”.

Dr Vuong Trieu, CEO and Chairman of Mateon said, "We are pleased to be able to leverage on the deep tradition of Indian medicine and advanced artificial intelligence and supercomputing technologies under one umbrella to create this innovative solution to healthcare, one which we hope to replicate throughout the world across multiple indications.” Dr. Trieu added,With our continued drive to remove inefficiencies from drug development and clinical trial processes, this platform sets the stage for continual improvement of drug development and clinical trials by democratizing the drug development process through patient-driven research.”

About PulmoHeal: Clinical data suggests that PulmoHeal efficacy is statistically significant and more than doubles the recovery rate of COVID-19 patients. These results have been published in a prestigious peer reviewed international journal Frontiers in Pharmacology and Clinical Pharmacology. More information available at www.pulmoheal.com.

About AI Telemedicine platform: Mateon’s AI telemedicine platform combines a mobile app called ArtiHealth for consumers to self-monitor their respiratory health using AI-driven logic. It also enables a post-marketing survey to allow crowd sourcing of data from patients to provide large scale real world clinical data necessary for a evaluation of PulmoHeal in respiratory diseases such as COPD and asthma. A QR code on the product package allows consumers to download the app on their mobile device. For additional information, please visit: www.pulmoheal.com.

About Windlas Biotech Pvt. Ltd, India: Windlas is a 20-year-old company with a strong track record of research, development, manufacturing, and distribution of pharmaceutical products in India, USA and several other emerging markets. It has four large scale manufacturing facilities employing more than 1500 employees and is the 5th largest Contract Development and Manufacturing Organization (CDMO) serving top innovator as well as generic pharma companies across the world. It has developed more than 500 different formulations (> 2Billion doses annually) of anti-viral, cardiovascular, anti-diabetic, anti-infective, CNS and dermatology products. For more information, please visit https://windlas.com/

About Mateon Therapeutics: Mateon was created by the 2019 merger with Oncotelic, which became a wholly owned subsidiary of Mateon, thereby creating an immuno-oncology company dedicated to the development of first in class RNA therapeutics as well as small molecule drugs against cancer and infectious diseases. OT-101, the lead immuno-oncology drug candidate of Mateon/Oncotelic, is a first-in-class anti-TGF-βRNA therapeutic that exhibited single agent activity in some relapsed/refractory cancer patients in clinical trial settings. OT-101 also has activity against SARS-CoV-2. Mateon/Oncotelic is seeking to leverage its deep expertise in oncology drug development to improve treatment outcomes and survival of cancer patients with a special emphasis on rare paediatric cancers. Mateon has rare paediatric designation for DIPG (OT-101), melanoma (CA4P), and AML (OXi4503). For more information, please visit www.oncotelic.com and www.mateon.com.

Mateon's Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this communication regarding strategy, future operations, future financial position, prospects, plans and objectives of management are forward-looking statements. Words such as “may”, “expect”, “anticipate” “hope”, “vision”, “optimism”, “design”, “exciting”, “promising”, “will”, “conviction”, "estimate," "intend," "believe", “quest for a cure of cancer”, “innovation-driven”, “paradigm-shift”, “high scientific merit”, “impact potential” and similar expressions are intended to identify forward-looking statements. Forward-looking statements contained in this press release include, but are not limited to, statements about future plans, the progress, timing, clinical development, scope and success of future clinical trials, the reporting of clinical data for the company’s product candidates and the potential use of the company’s product candidates to treat various cancer indications. Each of these forward-looking statements involves risks and uncertainties and actual results may differ materially from these forward-looking statements. Many factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data observed during preclinical or clinical studies, clinical trial site activation or enrollment rates that are lower than expected, changes in expected or existing competition, changes in the regulatory environment, failure of collaborators to support or advance collaborations or product candidates and unexpected litigation or other disputes. These risks are not exhaustive, the company faces known and unknown risks, including the risk factors described in the company’s annual report on Form 10-K filed with the SEC on April 10, 2019 and in the company’s other periodic filings. Forward-looking statements are based on expectations and assumptions as of the date of this press release. Except as required by law, the company does not assume any obligation to update forward-looking statements contained herein to reflect any change in expectations, whether as a result of new information future events, or otherwise.

Contact Information:
For Mateon Therapeutics, Inc.:
Amit Shah
ashah@oncotelic.com

******


Primary Logo

Source: Mateon Therapeutics, Inc.